Working… Menu

Cisplatin, Gemcitabine and Bevacizumab in Combination for Metastatic Transitional Cell Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00234494
Recruitment Status : Completed
First Posted : October 7, 2005
Results First Posted : March 14, 2016
Last Update Posted : March 14, 2016
Genentech, Inc.
Eli Lilly and Company
Walther Cancer Institute
Hoosier Cancer Research Network
Information provided by (Responsible Party):
Christopher Sweeney, MBBS, Hoosier Cancer Research Network

Brief Summary:

Cisplatin is a very important agent for the treatment of TCC as it has a single agent response rate of approximately 15%. However, it has been most important as a part of combination chemotherapy, MVAC initially and now in combination with gemcitabine. Single agent gemcitabine has demonstrated an overall response rate (ORR) of approximately 25%, including some complete responses (CR), with minimal toxicity in patients with advanced bladder cancer. Bevacizumab, a murine anti-human VEGF monoclonal antibody, has been advanced for use in combination with cytotoxic chemotherapy to delay time to disease progression in patients with metastatic solid tumors.

This trial is designed to further assess the efficacy, safety and tolerability of this regimen in this patient population.

Condition or disease Intervention/treatment Phase
Bladder Cancer Drug: Cisplatin Drug: Gemcitabine Drug: Bevacizumab Phase 2

  Show Detailed Description

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 45 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase II Trial of Cisplatin, Gemcitabine and Bevacizumab in Combination for Metastatic Transitional Cell Cancer: Hoosier Oncology Group GU04-75
Study Start Date : November 2005
Actual Primary Completion Date : December 2008
Actual Study Completion Date : December 2008

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: Single Group Assignment
Cisplatin + Gemcitabine + Bevacizumab
Drug: Cisplatin
Cisplatin 70 mg/m2, day 1

Drug: Gemcitabine
Gemcitabine 1250 mg/m2, day 1 and 8

Drug: Bevacizumab
Bevacizumab 15mg/kg, day 1

Primary Outcome Measures :
  1. Progression Free Survival [ Time Frame: 36 months ]
    - To determine the progression free survival of patients with metastatic transitional cell cancer treated with cisplatin, gemcitabine and bevacizumab.

Secondary Outcome Measures :
  1. Overall Survival Time [ Time Frame: 36 months ]
    To estimate overall survival time in months.

  2. Estimate Response Rates [ Time Frame: 36 months ]
    To estimate rate of partial response (PR), complete response (CR) and overall response (PR plus CR).

  3. Duration of Response for Responding Patients [ Time Frame: 36 months ]
    To estimate duration of response for responding patients.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Previously untreated or relapsed locally advanced or metastatic transitional cell carcinoma of the bladder. (Patients with pathology showing ANY component of non-transitional cell histology are not eligible).
  • Relapsed patients may have received prior chemotherapy ≥ one year prior to study registration as part of a neoadjuvant or adjuvant regimen and must not have had intervening therapy from the end of that treatment until study entry.
  • Measurable disease as per RECIST.
  • Prior radiation therapy, immunotherapy, cytokine, biologic or vaccine therapy must be greater than 28 days prior to being registered for protocol therapy,

Exclusion Criteria:

  • No known central nervous system metastasis. (imaging of brain only required if clinically indicated)
  • No prior organ allograft.
  • No history of other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug or that might affect the interpretation of the results of the study or render the subject at high risk from treatment complications.
  • No evidence of bleeding diathesis or coagulopathy.
  • No history of serious, non-healing wound, ulcer or bone fracture
  • No history of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within 6 months prior to being registered for protocol therapy.
  • No prior history of malignancy in the past 5 years with the exception of basal cell and squamous cell carcinoma of the skin. Other cancers with low potential for metastasis, such as in situ cancers (e.g., Grade 1, TA TCC (low grade superficial bladder cancer), colonic polyp with focus of adenocarcinoma) can also be enrolled after approval from the study chair.
  • No major surgical procedure, open biopsy, or significant traumatic injury less than 28 days prior to being registered for protocol therapy.
  • Patients are not eligible if the need for any major surgical procedure is anticipated during the course of the study.
  • Any minor surgical procedures, fine needle aspirations or core biopsies must be greater than 7 days prior to being registered for protocol therapy except procedures to secure a vascular access device which must be greater than 7 days prior to the start of protocol therapy.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00234494

Layout table for location information
United States, Illinois
University of Chicago
Chicago, Illinois, United States, 60637
Medical & Surgical Specialists, LLC
Galesburg, Illinois, United States, 61401
United States, Indiana
Oncology Hematology Associates of SW Indiana
Evansville, Indiana, United States, 47714
Fort Wayne Oncology & Hematology, Inc
Fort Wayne, Indiana, United States, 46815
Indiana University Cancer Center
Indianapolis, Indiana, United States, 46202
Quality Cancer Center (MCGOP)
Indianapolis, Indiana, United States, 46202
Arnett Cancer Care
Lafayette, Indiana, United States, 47904
Northern Indiana Cancer Research Consortium
South Bend, Indiana, United States, 46601
AP&S Clinic
Terre Haute, Indiana, United States, 47804
United States, Missouri
Siteman Cancer Center
St. Louis, Missouri, United States, 63110
United States, Ohio
Oncology Hematology Care, Inc.
Cincinnati, Ohio, United States, 45242
Sponsors and Collaborators
Christopher Sweeney, MBBS
Genentech, Inc.
Eli Lilly and Company
Walther Cancer Institute
Hoosier Cancer Research Network
Layout table for investigator information
Study Chair: Christopher Sweeney, M.B.B.S. Hoosier Oncology Group, LLC

Additional Information:
Publications of Results:
Layout table for additonal information
Responsible Party: Christopher Sweeney, MBBS, Sponsor-Investigator, Hoosier Cancer Research Network Identifier: NCT00234494     History of Changes
Other Study ID Numbers: HOG GU04-75
First Posted: October 7, 2005    Key Record Dates
Results First Posted: March 14, 2016
Last Update Posted: March 14, 2016
Last Verified: February 2016
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Urinary Bladder Neoplasms
Urologic Neoplasms
Urogenital Neoplasms
Neoplasms by Site
Urinary Bladder Diseases
Urologic Diseases
Antineoplastic Agents
Antineoplastic Agents, Immunological
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Growth Substances
Physiological Effects of Drugs
Growth Inhibitors
Antimetabolites, Antineoplastic
Molecular Mechanisms of Pharmacological Action
Antiviral Agents
Anti-Infective Agents
Enzyme Inhibitors
Immunosuppressive Agents
Immunologic Factors